Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer.
Renal cell carcinoma (RCC) is a heterogeneous disease as reflected in its presentation and clinical course, pathological subtypes, nuclear grades and molecular biology. Emerging data indicate that renal tumors express a variety of molecular tumor markers and unique patterns of gene expression. Clinically the disease behaves quite heterogeneously, with courses ranging from indolent to highly aggressive. Surgical monotherapy or as part of a multimodal approach remains the standard of care for most cases of RCC. Radical or partial nephrectomy is associated with a 5-year cancer specific survival (CSS) of 85-97% for pT1 tumors. Unfortunately, 20% of patients have either locally advanced or node positive (N+) RCC while another 22% have metastatic RCC (mRCC) at presentation. Unlike the outcomes in early localized disease, survival rates for N+ patients are poor and patients with mRCC are rarely cured despite aggressive multimodal therapy. Classic cytotoxic chemotherapy has repeatedly been shown to have little effect and only 5-20% of patients with mRCC respond to immunologic agents such as interferon and/or interleukin. Cytoreductive nephrectomy with systemic immunotherapy is associated with few cures with median survivals of 12-24 months. Recent advances in our understanding of the molecular origins and pathways of RCC have led to the development of more effective targeted therapies. Here we review the molecular pathways that define the pertinent therapeutic targets in RCC and the clinical data for these new and promising agents.
Haas
Naomi B
NB
Department of Medical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, 333 Cottman Avenue, Philadelphia, PA 19111, USA.
Uzzo
Robert G
RG
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000098:blood supply / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D007680:Kidney Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000201:enzymology; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases
Nat Genet. 1997 May;16(1):68-73
9140397
J Urol. 2006 Feb;175(2):459-62
16406971
Lancet Oncol. 2005 Jul;6(7):491-500
15992698
Blood. 2005 Feb 1;105(3):986-93
15459012
Invest New Drugs. 2005 Aug;23(4):357-61
16012795
Am J Pathol. 1999 Aug;155(2):517-26
10433944
Clin Cancer Res. 2004 Apr 15;10(8):2584-6
15102658
J Clin Oncol. 2006 Mar 20;24(9):1363-9
16446323
Blood. 2003 May 1;101(9):3597-605
12531805
Ann Surg Oncol. 2007 Feb;14(2):759-65
17103075
Ann Intern Med. 2006 Nov 7;145(9):660-4
17088579
Am J Pathol. 1994 Aug;145(2):356-64
7519827
J Urol. 2005 Jun;173(6):1889-92
15879769
Cancer. 2005 Dec 1;104(11):2323-33
16240452
Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):1047-52
11792863
Oncogene. 2000 Dec 27;19(56):6680-6
11426655
J Clin Oncol. 2005 May 1;23(13):2900-2
15860848
N Engl J Med. 2006 Dec 14;355(24):2542-50
17167137
Annu Rev Genet. 1986;20:231-51
2880556
N Engl J Med. 2005 Dec 8;353(23):2477-90
16339096
Urol Clin North Am. 2003 Aug;30(3):423-36
12953746
Ann Intern Med. 1984 Dec;101(6):798-9
6497196
J Urol. 2006 Feb;175(2):425-31
16406965
Mol Carcinog. 2001 Jul;31(3):161-70
11479925
Mol Cancer Ther. 2006 Apr;5(4):995-1006
16648571
Lancet. 2006 Oct 14;368(9544):1329-38
17046465
J Biol Chem. 1993 Oct 25;268(30):22825-9
8226793
Semin Oncol. 1995 Feb;22(1):3-8
7855617
N Engl J Med. 2007 Jan 11;356(2):115-24
17215529
Urol Clin North Am. 1993 May;20(2):303-21
8493752
Lancet. 2001 Sep 22;358(9286):966-70
11583750
N Engl J Med. 2003 Jul 31;349(5):427-34
12890841
J Clin Oncol. 2005 Aug 10;23(23):5294-304
15998902
CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
15661684
J Surg Oncol. 2005 Sep 1;91(3):173-80
16118771
Lancet. 2004 Feb 21;363(9409):594-9
14987883
Clin Cancer Res. 2003 Jan;9(1):327-37
12538485
Adv Cancer Res. 1998;72:141-96
9338076
Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001425
15674877
JAMA. 2006 Jun 7;295(21):2516-24
16757724
Curr Urol Rep. 2007 Jan;8(1):19-30
17239313
Eur J Cancer. 2006 Aug;42(12):1875-80
16806903
JAMA. 1995 Feb 15;273(7):564-70
7837390
N Engl J Med. 2001 Dec 6;345(23):1655-9
11759643
Hum Mol Genet. 1994 Dec;3(12):2169-73
7881415
Cancer Res. 2006 Jun 1;66(11):5549-54
16740688
N Engl J Med. 2007 May 31;356(22):2271-81
17538086
Ann Intern Med. 2005 Aug 16;143(4):313-4
16103482
Cancer. 2006 Nov 15;107(10):2375-83
17048248
N Engl J Med. 2007 Jan 11;356(2):125-34
17215530
J Clin Oncol. 2006 Oct 1;24(28):e48
17008686
Cancer Res. 2004 Oct 1;64(19):7099-109
15466206
J Urol. 2005 Jun;173(6):1903-7
15879772
Arch Dermatol. 2006 Nov;142(11):1477-9
17116839
Nature. 1994 Jun 30;369(6483):756-8
8008069